Omeros Corporation stock fell 2.06 percent as Yartemlea gains traction

Published on 10/07/2026 at 00:48 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Omeros Corporation stock posted USD 28.53 million in Q2 revenue and adjusted EPS of USD 0.02. Yartemlea reimbursement support began October 1, 2026.

OMER, US6821431029, Illustration mit AI erstellt.

Omeros Corporation stock (ISIN US6821431029) was last at USD 18.51 on Nasdaq on October 6, 2026, down 2.06 percent from the previous session. The latest quarterly report showed USD 28.53 million in revenue and adjusted EPS of USD 0.02, giving the market a sharper test of Yartemlea's commercial launch.

Quarterly figures reset expectations

According to MarketBeat on October 4, 2026, Omeros generated USD 28.53 million in the latest quarter, versus a USD 12.69 million consensus estimate. That is a 124.9 percent revenue beat, while adjusted EPS of USD 0.02 exceeded the consensus loss of USD 0.27 by USD 0.29.

The figures refer to the quarter ended June 30, 2026. Structured financial statements also show consolidated net income of USD 6.637 million for Q2 2026, compared with USD 51.249 million in Q1 2026, making the revenue line and Yartemlea uptake more important than a simple profit comparison.

Yartemlea reaches a reimbursement milestone

Yartemlea net revenue reached USD 28.5 million in Q2 2026, up 11 percent sequentially, according to TradingView. The same report says CMS NTAP status became effective on October 1, 2026, giving eligible hospitals additional Medicare reimbursement for the treatment of transplant-associated thrombotic microangiopathy.

That reimbursement date gives the commercial story a measurable checkpoint for the third quarter. It also leaves execution as the key variable, because the stock must translate initial product revenue into repeat demand while the company continues developing therapies for complement and immune-system disorders.

Analyst target remains above Nasdaq price

Investing.com reported on September 22, 2026, that Cantor Fitzgerald upgraded Omeros from Neutral to Overweight and set a USD 22.00 price target after reviewing Yartemlea's launch. The firm cited stronger-than-expected performance and physician feedback.

MarketBeat describes a Moderate Buy consensus from seven analysts, including three Buy ratings, one Strong Buy and three Holds. Its average 12-month target of USD 34.00 lies 83.7 percent above the October 6 price of USD 18.51.

Omeros stock stays below yearly high

OMER's October 6 Nasdaq range was USD 18.32 to USD 18.97, with volume of 1,031,484 shares. The stock's 52-week range is USD 4.06 to USD 21.24, so the last price stood USD 2.73 below the yearly high, a 12.9 percent gap.